Cara Therapeutics (CARA) Bullish Stance Reiterated at Needham & Company
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/18/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
Cara Therapeutics, Inc. (CARA) Posts Mixed Q4 Results
March 27, 2014 4:03 PM EDTCara Therapeutics, Inc. (NASDAQ: CARA) reported Q4 EPS of ($0.49), $0.31 worse than the analyst estimate of ($0.18). Revenue for the quarter came in at $1 million versus the consensus estimate of $1.52 million.
For earnings history and earnings-related data on (not found) (CARA) click here.... More
